newsfilter
← Latest News
Business Wire·

Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss

MANE
  • VDPHL01, an oral extended-release minoxidil formulation by Veradermics, demonstrated deepening of hair growth in the twice-daily (BID) arm & maintenance in the once-daily (QD) arm at Month 12 of Study 302 Part B.
  • Non-vellus hair counts increased by 43.9 hairs/cm² for the BID group & 29.7 hairs/cm² for the QD group from baseline to Month 12.
  • Patient-reported outcomes showed 89.1% (BID) & 79.8% (QD) reported visible improvement, with 68.0% (BID) & 48.4% (QD) reporting 'much improved' or 'improved' hair coverage.
  • Investigator Global Assessment scores indicated 92.2% (BID) & 74.4% (QD) of participants had improved hair coverage at Month 12.
  • The 12-month safety profile remained favorable with no new safety signals, no treatment-related serious adverse events, & no discontinuations due to adverse events.
  • Participants in the placebo group who crossed over to VDPHL01 after 6 months achieved non-vellus hair count increases of 32.1 hairs/cm² (BID) & 24.5 hairs/cm² (QD).
  • Study 302 enrolled 519 men with mild-to-moderate pattern hair loss randomized to VDPHL01 BID, VDPHL01 QD, or placebo.
  • Combined data from Study 302 Parts A & B & Study 304 support VDPHL01's potential as the first FDA-approved non-hormonal oral treatment for the 50 million men with pattern hair loss in the U.S.
  • Veradermics anticipates announcing data from the female pattern hair loss trial (Study 306) in the first half of 2027.
  • A conference call & webcast regarding these results were scheduled for 8:00 a.m. ET on the release date.